allantoin has been researched along with Tumor Lysis Syndrome in 2 studies
Tumor Lysis Syndrome: A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fernandes, J | 1 |
| de Amorim, GC | 1 |
| da Veiga, TE | 1 |
| Cardoso, J | 1 |
| Arruda, AC | 1 |
| Arruda, MSP | 1 |
| Castelo-Branco, MTL | 1 |
| Leach, M | 1 |
| Parsons, RM | 1 |
| Reilly, JT | 1 |
| Winfield, DA | 1 |
2 other studies available for allantoin and Tumor Lysis Syndrome
| Article | Year |
|---|---|
Allantoin reduces cell death induced by cisplatin: possible implications for tumor lysis syndrome management.
Topics: Allantoin; Apoptosis; Cell Death; Cell Line, Tumor; Cell Survival; Cisplatin; Humans; Hydrogen Perox | 2019 |
Efficacy of urate oxidase (uricozyme) in tumour lysis induced urate nephropathy.
Topics: Aged; Allantoin; Antimetabolites, Antineoplastic; Diuresis; Drug Evaluation; Female; Humans; Kidney | 1998 |